Xiaofeng Zhou1,2, GuoShuang Shen3, Dengfeng Ren1,3, Xinjian Guo2, Jingqi Han2, Qijing Guo1,4, Fuxing Zhao1,3, Miaozhou Wang1,3, Qiuxia Dong1,5, Zhanquan Li6,7, Jiuda Zhao8,9. 1. Research Center for High Altitude Medicine, Qinghai University, Xining, 810000, China. 2. Department of Pathology, Affiliated Hospital of Qinghai University, Xining, 810000, China. 3. Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Xining, 810000, China. 4. Medical Oncology, Affiliated Hospital of Qinghai University, Xining, 810000, China. 5. Department of Medical Oncology, The Fifth People's Hospital of Qinghai Province, Xining, 810001, China. 6. Research Center for High Altitude Medicine, Qinghai University, Xining, 810000, China. 13709758879@163.com. 7. Hematology Department, Affiliated Hospital of Qinghai University, Xining, 810000, China. 13709758879@163.com. 8. Research Center for High Altitude Medicine, Qinghai University, Xining, 810000, China. jiudazhao@126.com. 9. Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Xining, 810000, China. jiudazhao@126.com.
Abstract
PURPOSE: The expression of cytochrome B561 (CYB561) and its role in breast cancer (BC) prognosis remain unclear. We analyzed the differential expression and prognostic value of CYB561 using online databases and a clinical cohort through bioinformatics and immunohistochemistry. METHODS: The differential expression of CYB561 and its association with BC were analyzed using the tumor immune estimation resource (TIMER), gene expression profiling interaction analysis2 (GEPIA2), Human Protein Atlas, Cancer Cell Line Encyclopedia, and Kaplan-Meier Plotter website. Important pathways of CYB561 enrichment were explored using gene set enrichment analysis. Immunohistochemistry detected CYB561 expression in normal breast, breast hyperplasia, ductal carcinoma in situ (DCIS), para-cancer, and invasive BC groups. Association between CYB561 expression and BC prognosis was analyzed using Kaplan-Meier and Cox regression analyses. RESULTS: CYB561 mRNA expression was higher in GEPIA and TIMER BC patients than in para-cancer tissues. CYB561 was expressed in the glandular epithelium and myoepithelium, with positive localization in the cytoplasm and cell membrane. CYB561 protein expression significantly differed among the groups. CYB561 expression was correlated with ERBB2/HER2 and infiltrating CD4+ T cells in GEPIA and TIMER BC patients and associated with HER2 status, histological grade, and molecular subtypes in the clinical cohort but not related to tumor-infiltrating lymphocytes. CYB561 mRNA overexpression predicted reduced recurrence-free survival and overall survival in BC. Patients with CYB561 expression had significantly reduced overall survival and increased risk of death. CONCLUSION: CYB561 can serve as an effective clinical prognostic biomarker for BC.
PURPOSE: The expression of cytochrome B561 (CYB561) and its role in breast cancer (BC) prognosis remain unclear. We analyzed the differential expression and prognostic value of CYB561 using online databases and a clinical cohort through bioinformatics and immunohistochemistry. METHODS: The differential expression of CYB561 and its association with BC were analyzed using the tumor immune estimation resource (TIMER), gene expression profiling interaction analysis2 (GEPIA2), Human Protein Atlas, Cancer Cell Line Encyclopedia, and Kaplan-Meier Plotter website. Important pathways of CYB561 enrichment were explored using gene set enrichment analysis. Immunohistochemistry detected CYB561 expression in normal breast, breast hyperplasia, ductal carcinoma in situ (DCIS), para-cancer, and invasive BC groups. Association between CYB561 expression and BC prognosis was analyzed using Kaplan-Meier and Cox regression analyses. RESULTS: CYB561 mRNA expression was higher in GEPIA and TIMER BC patients than in para-cancer tissues. CYB561 was expressed in the glandular epithelium and myoepithelium, with positive localization in the cytoplasm and cell membrane. CYB561 protein expression significantly differed among the groups. CYB561 expression was correlated with ERBB2/HER2 and infiltrating CD4+ T cells in GEPIA and TIMER BC patients and associated with HER2 status, histological grade, and molecular subtypes in the clinical cohort but not related to tumor-infiltrating lymphocytes. CYB561 mRNA overexpression predicted reduced recurrence-free survival and overall survival in BC. Patients with CYB561 expression had significantly reduced overall survival and increased risk of death. CONCLUSION: CYB561 can serve as an effective clinical prognostic biomarker for BC.
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Dezheng Huo; Hai Hu; Suhn K Rhie; Eric R Gamazon; Andrew D Cherniack; Jianfang Liu; Toshio F Yoshimatsu; Jason J Pitt; Katherine A Hoadley; Melissa Troester; Yuanbin Ru; Tara Lichtenberg; Lori A Sturtz; Carl S Shelley; Christopher C Benz; Gordon B Mills; Peter W Laird; Craig D Shriver; Charles M Perou; Olufunmilayo I Olopade Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Gabriel Balmus; Domenic Pilger; Julia Coates; Mukerrem Demir; Matylda Sczaniecka-Clift; Ana C Barros; Michael Woods; Beiyuan Fu; Fengtang Yang; Elisabeth Chen; Matthias Ostermaier; Tatjana Stankovic; Hannes Ponstingl; Mareike Herzog; Kosuke Yusa; Francisco Munoz Martinez; Stephen T Durant; Yaron Galanty; Petra Beli; David J Adams; Allan Bradley; Emmanouil Metzakopian; Josep V Forment; Stephen P Jackson Journal: Nat Commun Date: 2019-01-08 Impact factor: 14.919
Authors: Sathana Dushyanthen; Paul A Beavis; Peter Savas; Zhi Ling Teo; Chenhao Zhou; Mariam Mansour; Phillip K Darcy; Sherene Loi Journal: BMC Med Date: 2015-08-24 Impact factor: 8.775